Saturday, 31 October 2026European Markets

SOLOCAL GROUP Stock Over 34% Up In The Last 21 Sessions

Loading stream...

(vianews) - shares of solocal group (cac 40: local.pa) jumped by a staggering 34.23% in 21 sessions from €0.12 to €0.16 at 05:07 est on wednesday, after two successive sessions in a row of gains. cac 40 is rising 0.11% to €7,209.00, following the last session's upward trend.

solocal group's last close was €0.16, 86.29% below its 52-week high of €1.20.

about solocal group

solocal group s.a. provides digital services in france and internationally. its services include connect that allows vses and smes to manage their digital presence on pagesjaunes and various web through mobile application, or a web interface, as well as manages interactions between professionals and their customers; and booster that allows companies to increase their digital visibility in the web. the company was formerly known as pagesjaunes groupe and changed its name to solocal group s.a. in june 2013. solocal group s.a. was founded in 1896 and is based in boulogne-billancourt, france.

earnings per share

as for profitability, solocal group has a trailing twelve months eps of €-0.02.

volume

today's last reported volume for solocal group is 177554 which is 89.2% below its average volume of 876628.

revenue growth

year-on-year quarterly revenue growth declined by 6.9%, now sitting on 400m for the twelve trailing months.

yearly top and bottom value

solocal group's stock is valued at €0.16 at 05:07 est, way under its 52-week high of €1.20 and way higher than its 52-week low of €0.12.

moving average

solocal group's value is way below its 50-day moving average of €0.32 and way below its 200-day moving average of €0.62.

more news about solocal group (local.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com